Compare Davita Inc (DVA) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs ArcelorMittal SA — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while ArcelorMittal SA trades at $64.11 (market cap $45.70B). The key difference: ArcelorMittal SA is far larger — about 4× Davita Inc's market cap, and ArcelorMittal SA pays a 0.98% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and ArcelorMittal SA for 36 Days on average.
| DVA | MT | |
|---|---|---|
Market Cap | $11.29B | $45.70B |
Volume | 582,204 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $78.74 |
52-Week Low | $103.87 | $36.91 |
Typical Hold Time | 114 Days | 36 Days |
Enterprise Value | $24.01B | $55.27B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.
DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.
ArcelorMittal (MT) trades at $61.30, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company shows mixed fundamentals with declining revenue trends from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational challenges including a $1B impairment charge from Ukrainian plant closures due to missile strikes, while analyst consensus remains positive with a $74.33 price target.
The stock presents a value opportunity with attractive valuation ratios (P/S 0.75, P/B 0.84) and strong analyst support (52% buy ratings), but faces significant operational risks from geopolitical exposure and declining cash flow trends. Near-term performance depends on European demand recovery and successful execution of growth projects amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
